AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine's drug target
Number of subjects: 0
Study 36254140 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter balloon dilation combined with cold fluid compensatory swallowing
Number of subjects: 0
Study 36254140 — intervention group
Group type: COMPARATOR
Intervention: Catheter balloon dilation
Number of subjects: 0
Study 33445213 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (AST) supplementation, 8 mg/d for 8 weeks
Number of subjects: 44
Study 33445213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32330107 — intervention group
Group type: EXPERIMENTAL
Intervention: KCA (7g BHB, 100mg caffeine, amino acids)
Number of subjects: 24
Study 32330107 — intervention group
Group type: COMPARATOR
Intervention: Water (control condition)
Number of subjects: 24
Study 34431993 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction
Number of subjects: 48282
Study 34431993 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction
Number of subjects: 48282
Study 34431993 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for type 1 and type 2 myocardial infarction
Number of subjects: 48282
Study 34431993 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of type 2 events
Number of subjects: 48282
Study 34431993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex as a predictor
Number of subjects: 48282
Study 33536283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid, pyrazinamide, rifampicin, moxifloxacin (individual and in combination)
Number of subjects: 160
Study 33536283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 160
Study 33536283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and pyrazinamide (combination)
Number of subjects: 160
Study 33536283 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT imaging
Number of subjects: 160
Study 34605947 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab (2 or 4 mg/kg b.w.)
Number of subjects: 301
Study 34605947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 616388368 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nursing intervention measures plus conventional nursing
Number of subjects: 120
Study 616388368 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 120
Study 36881396 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 562
Study 36881396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 34008876 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Steiger approach
Number of subjects: 0
Study 34008876 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Steiger method applied to COPDGene study
Number of subjects: 0
Study 33275382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise intervention (Healthy Body Healthy Mind) plus usual care
Number of subjects: 13
Study 35986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina 500 mg twice daily along with topical triamcinolone acetonide 0.1% thrice daily for one week
Number of subjects: 60
Study 35986466 — intervention group
Group type: COMPARATOR
Intervention: Topical triamcinolone acetonide 0.1% alone thrice daily for 8 weeks
Number of subjects: 60
Study 35777696 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-Pain and Sadness Support (HIVPASS) intervention
Number of subjects: 0
Study 35777696 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) condition
Number of subjects: 0
Study 35162263 — intervention group
Group type: COMPARATOR
Intervention: Control (gentle touch + human voice)
Number of subjects: 114
Study 35162263 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + breast milk odor
Number of subjects: 114
Study 35162263 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + breast milk odor + breast milk taste
Number of subjects: 114
Study 33734575 — intervention group
Group type: EXPERIMENTAL
Intervention: LONGTY DCB
Number of subjects: 211
Study 33734575 — intervention group
Group type: COMPARATOR
Intervention: SeQuent Please DCB
Number of subjects: 211
Study 32639800 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum information scrambling on a 10-qubit trapped-ion quantum simulator
Number of subjects: 10
Study 32639800 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoherence analysis
Number of subjects: 10
Study 34982738 — intervention group
Group type: EXPERIMENTAL
Intervention: IV vitamin C (1,000 mg bolus over 30 minutes followed by continuous infusion of 250 mg/hr for 96 hours)
Number of subjects: 124
Study 34982738 — intervention group
Group type: EXPERIMENTAL
Intervention: IV vitamin C
Number of subjects: 124
Study 34982738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 124
Study 33949215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention fostering self-efficacy and social support through weekly, family-centered sessions
Number of subjects: 136
Study 33125362 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT+RF-IMRT
Number of subjects: 200
Study 33125362 — intervention group
Group type: COMPARATOR
Intervention: CF-IMRT
Number of subjects: 200
Study 34726703 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS (15 g) with FeFum (14 mg)
Number of subjects: 11
Study 34726703 — intervention group
Group type: COMPARATOR
Intervention: Control (FeFum 14 mg without GOS)
Number of subjects: 11
Study 34726703 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS and SF interaction
Number of subjects: 11
Study 34408611 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapulothoracic MWM + corrective exercises + tape
Number of subjects: 40
Study 34408611 — intervention group
Group type: COMPARATOR
Intervention: Corrective exercises + tape
Number of subjects: 40
Study 34408611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 34408611 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 40
Study 33301338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 128
Study 33301338 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 128
Study 33135385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment program (PEP) combined with cognitive training (CT) for 10 weeks
Number of subjects: 139
Study 33135385 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 139
Study 35720910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent wearable device combined with IARA and Orem self-care model
Number of subjects: 60
Study 35720910 — intervention group
Group type: COMPARATOR
Intervention: IARA intervention model combined with Orem self-care model
Number of subjects: 60
Study 34314615 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen (FIO2)
Number of subjects: 178
Study 34314615 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen (FIO2)
Number of subjects: 178
Study 35583400 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) combined with physiotherapy
Number of subjects: 52
Study 35583400 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 52
Study 33749992 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet gel (PG)
Number of subjects: 0
Study 32139353 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EE)
Number of subjects: 24
Study 32139353 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 24
Study 34498896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovering Together (RT)
Number of subjects: 58
Study 34630103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 66
Study 34630103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36142984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-plane ultrasonic scan-assisted spinal anesthesia (Group B)
Number of subjects: 120
Study 36142984 — intervention group
Group type: COMPARATOR
Intervention: Single-plane ultrasonic scan-assisted spinal anesthesia (Group A)
Number of subjects: 120
Study 33395140 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 347
Study 33395140 — intervention group
Group type: COMPARATOR
Intervention: No transversus abdominis plane block
Number of subjects: 347
Study 36374528 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tebipenem via NGT
Number of subjects: 12
Study 36374528 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tebipenem via NGT with enteral feeds
Number of subjects: 12
Study 36374528 — intervention group
Group type: COMPARATOR
Intervention: Whole tablet oral administration (reference formulation)
Number of subjects: 12
Study 33256796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 4 weeks
Number of subjects: 60
Study 33256796 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment for 4 weeks
Number of subjects: 60
Study 34090773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (oat bran) supplement (30 g/d, containing DF 8.9 g)
Number of subjects: 50
Study 34090773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (oat bran) supplement
Number of subjects: 50
Study 35394413 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training program (4 sets of 8 repetitions, 10 repetition maximum load, 5 min rest between sets and exercises)
Number of subjects: 39
Study 35394413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-redistribution training program (16 sets of 2 repetitions, 1 min rest between sets, 5 min rest between exercises)
Number of subjects: 39
Study 35394413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 33784885 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization methods for identifying rules of interaction
Number of subjects: 0
Study 34924237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1131
Study 34924237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1131
Study 34924237 — intervention group
Group type: EXPERIMENTAL
Intervention: SNT > 4 hours in high-risk group
Number of subjects: 1131
Study 33588087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg LOR
Number of subjects: 695
Study 33588087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.23 mg LOR
Number of subjects: 695
Study 33588087 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 695
Study 33099300 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35099281 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% basal insulin reduction applied 40 minutes before exercise onset (T-40)
Number of subjects: 20
Study 35099281 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% basal insulin reduction applied 90 minutes before exercise onset (T-90)
Number of subjects: 20
Study 35099281 — intervention group
Group type: COMPARATOR
Intervention: Comparison between T-40 and T-90
Number of subjects: 20
Study 33045417 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million MPCs with HA
Number of subjects: 100
Study 33045417 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 million MPCs with HA
Number of subjects: 100
Study 33045417 — intervention group
Group type: COMPARATOR
Intervention: HA vehicle control
Number of subjects: 100
Study 33045417 — intervention group
Group type: COMPARATOR
Intervention: Saline control (placebo)
Number of subjects: 100
Study 33423376 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 17
Study 33423376 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 17
Study 32992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance exercise followed by self‐myofascial release (CEBR)
Number of subjects: 26
Study 32992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric‐only exercise (ECC)
Number of subjects: 26
Study 32992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric jumps (PLY)
Number of subjects: 26
Study 32992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance exercise
Number of subjects: 26
Study 32992998 — intervention group
Group type: COMPARATOR
Intervention: Non-trained leg
Number of subjects: 26
Study 35803494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-in-1 design with graphical approach
Number of subjects: 0
Study 34283040 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive experience using a mobile phone-based head-mounted display
Number of subjects: 90
Study 34283040 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam sedation
Number of subjects: 90
Study 34283040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 34788593 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG-LASIK
Number of subjects: 44
Study 34788593 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 44
Study 34106628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage
Number of subjects: 180
Study 34106628 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 180
Study 34106628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage combined with relaxation therapy
Number of subjects: 180
Study 34106628 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 180
Study 34014714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Peer Support (VPS)
Number of subjects: 166
Study 34014714 — intervention group
Group type: COMPARATOR
Intervention: Peer support services-as-usual
Number of subjects: 166
Study 36240693 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-ideal social media images
Number of subjects: 260
Study 36240693 — intervention group
Group type: COMPARATOR
Intervention: Average size social media images
Number of subjects: 260
Study 33564835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax (H)
Number of subjects: 66
Study 33564835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-Hyrax (HH)
Number of subjects: 66
Study 33564835 — intervention group
Group type: EXPERIMENTAL
Intervention: Keles keyless expander (K)
Number of subjects: 66
Study 35804049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 61
Study 35804049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32870340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 94
Study 32870340 — intervention group
Group type: COMPARATOR
Intervention: Vaginal mesh hysteropexy
Number of subjects: 94
Study 35506334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem immediate release (IR)
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Untreated insomnia
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Lemborexant vs Suvorexant
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Lemborexant vs Zolpidem-IR
Number of subjects: 0
Study 35506334 — intervention group
Group type: COMPARATOR
Intervention: Lemborexant vs Untreated insomnia
Number of subjects: 0
Study 33274588 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use negative pressure dressing (SUNPD)
Number of subjects: 840
Study 33274588 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's preference of dressing
Number of subjects: 840
Study 35916755 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + TAU (n = 23)
Number of subjects: 49
Study 35916755 — intervention group
Group type: COMPARATOR
Intervention: TAU (n = 26)
Number of subjects: 49
Study 32310620 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 145 µg
Number of subjects: 254
Study 32310620 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 290 µg
Number of subjects: 254
Study 32310620 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 254
Study 36906404 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD (high-dose quadrivalent inactivated influenza vaccine) administered intramuscularly (IM)
Number of subjects: 2100
Study 36906404 — intervention group
Group type: COMPARATOR
Intervention: IIV4-SD (standard-dose influenza vaccine) administered subcutaneously (SC)
Number of subjects: 2100
Study 33260212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer input intervention
Number of subjects: 28
Study 33260212 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 34098686 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualized saphenous nerve block combined with periarticular infiltration analgesia (Group VSNB+PIA)
Number of subjects: 100
Study 34098686 — intervention group
Group type: COMPARATOR
Intervention: Only periarticular infiltration analgesia (Group PIA)
Number of subjects: 100
Study 33201245 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based rehabilitation (VR) in addition to standard care (SC)
Number of subjects: 0
Study 33201245 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 0
Study 32981097 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 0
Study 32981097 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 36048453 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX (oxaliplatin, 85 mg/m2; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; fluorouracil, 2400 mg/m2, every 2 weeks)
Number of subjects: 493
Study 36048453 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks)
Number of subjects: 493
Study 36048453 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX
Number of subjects: 493
Study 36048453 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 493
Study 33628758 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted anti-inflammatory diet
Number of subjects: 81
Study 32815838 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Elbow Arthroplasty (TEA)
Number of subjects: 664
Study 32815838 — intervention group
Group type: COMPARATOR
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 664
Study 35121633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate smoking cessation support with pharmacotherapy
Number of subjects: 115
Study 35121633 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Very Brief Advice to quit and signposting to smoking cessation services)
Number of subjects: 115
Study 34373201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocufilcon D (hydrogel) contact lenses
Number of subjects: 20
Study 34373201 — intervention group
Group type: EXPERIMENTAL
Intervention: Somofilcon A (silicone hydrogel) contact lenses
Number of subjects: 20
Study 34373201 — intervention group
Group type: COMPARATOR
Intervention: Both contact lenses
Number of subjects: 20
Study 33397410 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners' intention to provide breastfeeding appreciation
Number of subjects: 128
Study 33397410 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners' intention to provide breastfeeding presence
Number of subjects: 128
Study 33397410 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners' intention to provide breastfeeding responsiveness
Number of subjects: 128
Study 33397410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous mothers' perceptions of partners' breastfeeding savvy
Number of subjects: 128
Study 33397410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous mothers' perceptions of partners' breastfeeding help
Number of subjects: 128
Study 35570289 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connections - SBD (FC-SBD)
Number of subjects: 0
Study 35570289 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual Optimized (TAU-O)
Number of subjects: 0
Study 33752741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg twice daily for 14 days
Number of subjects: 1220
Study 33752741 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control arm)
Number of subjects: 1220
Study 33752741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 1220
Study 34644618 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified electroconvulsive therapy (MECT)
Number of subjects: 64
Study 34644618 — intervention group
Group type: COMPARATOR
Intervention: Control group (drugs alone)
Number of subjects: 64
Study 32567975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-engaging intervention
Number of subjects: 891
Study 32567975 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic intervention
Number of subjects: 891
Study 32567975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 891
Study 33788249 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow‐I with automated gas control
Number of subjects: 160
Study 33788249 — intervention group
Group type: EXPERIMENTAL
Intervention: Aisys with automated gas control
Number of subjects: 160
Study 33788249 — intervention group
Group type: COMPARATOR
Intervention: Conventional low flow anaesthesia (Flow‐I)
Number of subjects: 160
Study 33788249 — intervention group
Group type: COMPARATOR
Intervention: Conventional low flow anaesthesia (Aisys)
Number of subjects: 160
Study 32302693 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat, 40 mg daily during acute gout attack
Number of subjects: 52
Study 32302693 — intervention group
Group type: COMPARATOR
Intervention: Control group (febuxostat, 40 mg daily after attacks)
Number of subjects: 52
Study 32302693 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat and Control
Number of subjects: 52